Stockholders' Deficiency (Tables)

12 Months Ended

Mar. 31, 2020

Schedule of Warrants Outstanding

Warrant issuances, exercises and expirations or cancellations during the years ended March 31, 2020 and 2019, were as follows, resulting in warrants outstanding at the end of those respective periods:

	Broker Warrants			Consultant and Noteholder Warrants			Warrants Issued on Conversion of Convertible Notes		Private Placement Warrants		Total
As at December 31, 2015		271,742			380,000			-		-		651,742
RTO adjustment*		53,507			74,860			-		-		128,367
After RTO		325,249			454,860			-		-		780,109
Less: Exercised		-			(131,365	)		-		-		(131,365	)
Less: Expired/cancelled		-			(285,279	)		-		-		(285,279	)
Add: Issued		55,433			878,250			-		390,744		1,324,427
As at March 31, 2017		380,682			916,466			-		390,744		1,687,892
Less: Exercised		(222,690	)		(140,000	)		-		-		(362,690	)
Less: Expired/cancelled		(19,935	)		(380,300	)		-		-		(400,235	)
Add: Issued		246,095			273,806			2,734,530		772,978		4,027,409
As at March 31, 2018		384,152			669,972	**		2,734,530		1,163,722		4,952,376
Less: Exercised		(62,838	)		-			-		-		(62,838	)
Less: Expired/cancelled		-			(342,416	)		-		-		(342,416	)
Add: Issued		-			849,601			-		-		849,601
As at March 31, 2019		321,314			1,177,157	**		2,734,530		1,163,722		5,396,723
Less: Expired/cancelled		-			(148,750	)		-		-		(148,750	)
Add: Issued		-			1,021,430			-		-		1,021,430
As at March 31, 2020		321,314			2,049,837	**		2,734,530		1,163,722		6,269,403
Exercise Price		$0.78-$3.00			$0.48-$7.59			2.00		3.00
Expiration Date		March 2022 to July 2022			April 2020 to March 2023			March 2020 to November 2022		April 2020 to July 2020

*As explained above, on February 2, 2016 all outstanding warrants at that time had been increased by a factor of 1.197.

**Consultant Warrants do not include 188,806 warrants provided to an officer of the Company as compensation while he was not a member of any Company options plan, otherwise disclosed in Note 9 under stock-based compensation.

Schedule of Fair Value of Option Granted Using Valuation Assumptions

The fair value of each option granted is estimated at the time of grant using multi-nominal lattice model using the following assumptions, for each of the respective years ended March 31:

	2020		2019		2018
Exercise price ($)		1.40-2.00		1.40-2.00		3.69-7.59
Risk free interest rate (%)		0.52-2.81		2.27-2.81		1.98-2.39
Expected term (Years)		2.0-3.0		2.0-3.0		3.0
Expected volatility (%)		97.8-141.1		97.8-141.1		139.75-145.99
Expected dividend yield (%)		0.00		0.00		0.00
Fair value of option ($)		0.76		0.588		1.032
Expected forfeiture (attrition) rate (%)		0.00		0.00		0.00

2015 Equity Incentive Plan [Member]

Schedule of Stock Option Activities

The following table summarizes the stock option activities of the Company:

	Number of options			Weighted average exercise price ($)
Granted		3,591,000			0.0001
Exercised		(3,390,503	)		0.0001
Outstanding as of December 31, 2015		200,497			0.0001
Cancelled during 2016		(35,907	)		0.0001
Outstanding as of March 31, 2018		164,590			0.0001
Exercised		(164,590	)		0.0001
Outstanding as of March 31, 2020 and 2019		-			-

2016 Equity Incentive Plan [Member]

Schedule of Stock Option Activities

	Number of options			Weighted average exercise price ($)
Granted		2,709,998			2.2031
Exercised		-			-
Outstanding as of March 31, 2017		2,709,998			2.2031
Granted		1,437,500			5.1676
Exercised		-			-
Outstanding as of March 31, 2018		4,147,498			3.2306
Granted		270,521			1.8096
Exercised		-			-
Outstanding as of March 31, 2019		4,418,019			3.1436
Granted		88,100			0.7763
Expired		(112,509	)		2.723
Exercised		-			-
Outstanding as of March 31, 2020		4,393,610			3.1069